Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | ACTION: ONC201 in H3 K27M–mutant diffuse midline glioma

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the Phase III ACTION trial (NCT05580562), evaluating ONC201 (dordaviprone) in H3 K27M–mutant diffuse midline glioma. H3 K27M-mutant diffuse gliomas are typically inoperable and insensitive to chemotherapy, where current treatment only consists of radiotherapy, with poor prognosis. ONC201 is a dopamine receptor D2/3 inhibitor that demonstrates a durable and good response rate in patients with mutant diffuse midline glioma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.